NTRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Natera Inc (NTRA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, positive analyst sentiment, hedge fund buying activity, and innovation in its product line make it a compelling choice. Despite some short-term challenges like zero net income, the long-term growth potential outweighs these concerns.
The stock's MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 59.766, suggesting no overbought or oversold conditions. The stock is trading near its resistance level (R1: 218.446), with key support at 205.756. Moving averages are converging, indicating potential consolidation or a breakout.
Record Q4 2025 earnings with 40% YoY revenue growth and a 56% increase in tests processed.
Positive analyst sentiment with multiple Buy ratings and raised price targets (up to $300).
Hedge funds are significantly increasing their holdings (265.72% increase in buying).
Ongoing innovation with the Phase 2 study of the Signatera ctDNA test.
Stanley Druckenmiller's portfolio includes a 13.2% allocation to Natera, indicating confidence from a high-profile investor.
Net income and EPS dropped to zero in Q4 2025, reflecting profitability challenges.
Options data indicates short-term bearish sentiment with a Put-Call Volume Ratio of 1.
Stock trend analysis shows limited short-term price movement potential.
Natera reported strong Q4 2025 revenue growth of 39.79% YoY to $665.5 million, with a gross margin increase to 66.93%. However, net income and EPS dropped to zero, indicating profitability challenges despite revenue growth.
Analysts are overwhelmingly positive on Natera, with multiple Buy ratings and raised price targets ranging from $205 to $300. Citi highlights Natera's dominant position in the molecular residual disease market and significant growth potential, while other firms emphasize strong fundamentals and sector momentum.
